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background:  Microvascular obstruction (MVO) is an independent predictor of outcomes in STEMI. Metoprolol reduced infarct size and improved 
LVEF in the METOCARD-CNIC trial (Circulation 2013). Here we evaluate its effect on MVO and causal mechanism.
methods: STEMI patients were randomized to pre-reperfusion iv metoprolol (15mg) or control. Magnetic resonance (CMR) was done 1 week post-
STEMI. MVO was defined as absence of contrast wash-in inside the Gad delayed enhancement (DE) area. The effect of metoprolol on ADP-induced 
platelet-neutrophil coaggregates (known mediator of MVO) was evaluated in other set of patients undergoing PCI.
results: 220 patients underwent CMR and MVO evaluation. Metoprolol reduced MVO: 2.9 g vs 4.7 in controls (95% CI difference 0.6/3.0 g, 
p=.003). This effect was maintained after adjusting for sex, age, ischemia duration, diabetes, and use of thrombectomy or GP IIb/IIIa inhib. To rule 
out that the effect was driven by infarct size reduction, MVO was further assessed as % of the DE-Gd area. Metoprolol patients showed a reduction 
in MVO: 9.1% of DE area vs. 11.9% in controls (95% CI difference 0.6/5.0 %, p=.01).  Metoprolol significantly reduced the presence of platelet-
neutrophil coaggregates in patients undergoing PCI.
Conclusion: Pre-reperfusion metoprolol in STEMI patients significantly reduced the incidence and extent of MVO, even after normalization for 
infarct size. Platelet-neutrophil co-aggregates inhibition by metoprolol might be implicated in this cardioprotective effect.
